Methods and compositions for preventing and treating a disease related to glycan dysregulation
Contemplated compositions and methods are directed to prevent and/or treat various autoimmune diseases that are typically associated with glycan dysregulation, and especially autoimmune demyelinating diseases. Further especially contemplated aspects include animal models and systems for screening compounds to treat and/or prevent such diseases.
1. A method for treating insulin-dependent diabetes mellitus comprising administering to a subject having insulin-dependent diabetes mellitus a pharmaceutical composition comprising N-acetylglucosamine (GlcNAc) and a pharmaceutically acceptable carrier,
wherein the level of Mgat5 modified glycans is increased in the subject, thereby treating the subject's insulin-dependent diabetes mellitus.
2. The method of claim 1 , further comprising administering a hexosamine pathway metabolite.
3. The method of claim 2 , wherein GlcNAc and the hexosamine pathway metabolite are administered in synergistic quantities.
4. The method of claim 2 , further comprising administering uridine, uridine 5′ diphosphate (UDP), uridine 5′ monophosphate (UMP), uridine 5′ triphosphate (UTP), glutamine or uracil.
5. The method of claim 4 , further comprising administering Vitamin D3.
6. The method of claim 2 , wherein the composition is administered orally.
7. The method of claim 1 , further comprising administering uridine, uridine 5′ diphosphate (UDP), uridine 5′ monophosphate (UMP), uridine 5′ triphosphate (UTP), glutamine or uracil.
8. The method of claim 7 , further comprising administering Vitamin D3.
9. The method of claim 1 , wherein the composition is administered orally.
10. A method for treating insulin-dependent diabetes mellitus comprising administering to a subject having insulin-dependent diabetes mellitus a pharmaceutical composition comprising N-acetylglucosamine (GlcNAc) and a compound selected from uridine, uridine 5′ diphosphate (UDP), uridine 5′ monophosphate (UMP), uridine 5′ triphosphate (UTP), glutamine or uracil, and a pharmaceutically acceptable carrier,
wherein the level of Mgat5 modified glycans is increased in the subject, thereby treating the subject's insulin-dependent diabetes mellitus.
11. The method of claim 10 , further comprising administering Vitamin D3.
12. The method of claim 11 , wherein the composition is administered orally.
13. The method of claim 10 , wherein the composition is administered orally.